13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03774407
(ClinicalTrials.gov)
June 20, 20195/12/2018Vaginal Estriol in Multiple SclerosisDual Benefits of Vaginal Estriol: Improved Urogenital Health and Re-myelination in Relapsing Remitting Multiple Sclerosis (RRMS)Multiple Sclerosis;Neurogenic BladderDrug: vaginal estriolTexas Tech University Health Sciences CenterNULLCompleted40 Years65 YearsFemale21Phase 2/Phase 3United States
2NCT01466114
(ClinicalTrials.gov)
October 201131/10/2011Estriol Treatment in Multiple Sclerosis (MS): Effect on CognitionA Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.Relapsing-remitting Multiple Sclerosis;Secondary-progressive Multiple Sclerosis;Primary-progressive Multiple SclerosisDrug: estriol;Other: Placebo;Drug: Norethindrone;Other: Progestin PlaceboUniversity of California, Los AngelesNULLRecruiting18 Years55 YearsFemale64Phase 2United States
3NCT00451204
(ClinicalTrials.gov)
March 200722/3/2007A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)A Combination Trial of Copaxone Plus Estriol in RRMSRelapsing Remitting Multiple SclerosisDrug: Estriol;Drug: Placebo;Drug: CopaxoneUniversity of California, Los AngelesWashington University School of Medicine;University of Texas Southwestern Medical Center;Ohio State University;University of Medicine and Dentistry of New Jersey;University of Chicago;University of Utah;Johns Hopkins University;University of Kansas Medical Center;University of Minnesota, MN;Mayo Clinic;University of Colorado, Aurora;University of New Mexico;University of Pennsylvania;Dartmouth-Hitchcock Medical Center;National Multiple Sclerosis Society;National Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS)Completed18 Years50 YearsFemale158Phase 2United States;Canada